CA Patent

CA3037328A1 — Tofacitinib oral sustained release dosage forms

Assigned to Pfizer Inc · Expires 2014-09-25 · 12y expired

What this patent protects

The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics. More particularly, there is provided a once daily pharmaceutical dosa…

USPTO Abstract

The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics. More particularly, there is provided a once daily pharmaceutical dosage form comprising a core comprising 22 mg of tofacitinib, or an equivalent amount of tofacitinib in the form of a pharmaceutically acceptable salt thereof, and an osmagen, and a semi-permeable membrane coating surrounding the core wherein said coating comprises a water-insoluble polymer.

Drugs covered by this patent

Patent Metadata

Patent number
CA3037328A1
Jurisdiction
CA
Classification
—
Expires
2014-09-25
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.